Diabetes
Refine Search
Pharmaceutical
Danish drugmaker Novo Nordisk’s GLP-1 receptor agonist Wegovy (semaglutide) has been approved in China for long-term weight management. 26 June 2024
Pharmaceutical
NeuroBo Pharmaceuticals (Nasdaq: NRBO), a clinical-stage biotechnology company focused on cardiometabolic diseases, has raised around $70 million through a private share placement. 26 June 2024
Pharmaceutical
Danish diabetes and weight loss giant Novo Nordisk (NOV: N) has announced plans to invest $4.1 billion to build a second fill and finishing manufacturing facility in Clayton. 25 June 2024
Pharmaceutical
Following on from warnings made by national regulators and Novo Nordisk, the World Health Organization (WHO) has become the latest to warn about falsified semaglutide. 21 June 2024
Pharmaceutical
The Swiss company Swixx BioPharma has stopped the supplies of Humalog insulin (insulin lispro) to Russia due to the decision of its manufacturer, the American pharma major Eli Lilly, The Pharma Letter’s local correspondent reports. 19 June 2024
Pharmaceutical
AstraZeneca’s Farxiga (dapagliflozin) has received approval from the US Food and Drug Administration to improve glycemic control in children with type-2 diabetes (T2D). 13 June 2024
Pharmaceutical
US Senator Bernie Sanders, chairman of the Senate Committee on Health, Education, Labor and Pensions (HELP), has announced that members will vote next week on whether to subpoena Doug Langa, senior vice president, head of North America operations and president of Novo Nordisk. 12 June 2024
Generics
Indian generics drugmaker Cadila Pharmaceuticals, together with the Russian investment fund the Russian Direct Investment Fund (RDIF), will invest more than 10 billion roubles ($112 million) in the establishment of a pharmaceutical complex and an injection drug plant in Russia. 11 June 2024
Pharmaceutical
Global biopharma firm Structure Therapeutics has announced the pricing of an expanded public offering, aiming to raise $476 million. 7 June 2024
Pharmaceutical
Shares in Californian company Biomea Fusion were down almost 60% ahead of the opening bell on Friday, after news of a regulatory setback. 7 June 2024
Pharmaceutical
The race to secure market share for GLP-1 agonists continues to develop, with Eli Lilly revealing more promising results for its option, tirzepatide. 6 June 2024
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended eight novel drugs for approval at its May 2024 meeting. 31 May 2024
Pharmaceutical
New research published in Nature Communications shows another potential application for GLP-1 agonists, adding to established benefits in type 2 diabetes, obesity and heart disease. 30 May 2024
Pharmaceutical
With its potential to revolutionize type 2 diabetes (T2D) treatment, Chinese firm Innovent Biologics’ (HKG: 1801) mazdutide's success could reshape the landscape of diabetes therapeutics in China. 25 May 2024
Pharmaceutical
Already a blockbuster diabetes and weight loss drug sold by Novo Nordisk under the brand names Ozempic, Rybelsus and Wegovy, semaglutide’s standing has been further enhanced by new findings. 24 May 2024
Generics
Indian biotech major Biocon has signed an exclusive licensing and supply agreement with South Korea’s Handok, for the commercialization of its vertically integrated, complex drug product, synthetic liraglutide. 24 May 2024
Pharmaceutical
US pharma major Eli Lilly today revealed that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion. 24 May 2024
Biotechnology
A well-financed US start-up has in-licensed three obesity drug candidates from Chinese drugmaker Jiangsu Hengrui Pharmaceuticals. 17 May 2024
Pharmaceutical
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin mimetic medicines for the treatment of type 2 diabetes and obesity, and an ever more active sector for the pharma industry. 17 May 2024
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze